Klotho Neurosciences, INC Form 4 insider transactions

Jason David Sawyer, a Director of Klotho Neurosciences, Inc., purchased 240,000 shares of common stock on July 22, 2026 for $0.23 per share.

Jon Mcgarity, a Director of Klotho Neurosciences, Inc., purchased 140,000 shares of common stock on July 20, 2026 for $0.18 per share.

Jeff Leblanc, Chief Financial Officer of Klotho Neurosciences, Inc., purchased 1,400,000 shares of common stock on July 16, 2026 for $0.18 per share.

Klotho Neurosciences' Chief Financial Officer, Jeff LeBlanc, acquired 2.5 million shares of common stock through an equity incentive plan grant.

Klotho Neurosciences Director Riad El-Dada acquired 350,000 shares of common stock through an equity incentive plan grant.

Klotho Neurosciences Director Samuel M. Zentman acquired 350,000 shares of common stock through an equity incentive plan, increasing his direct beneficial ownership to 1,086,440 shares.

Klotho Neurosciences, Inc. Director Shalom Hirschman was granted 350,000 shares of common stock under the company's Equity Incentive Plan, increasing his beneficial ownership to 908,873 shares.

Klotho Neurosciences director Jon McGarity received a grant of 350,000 common shares under the company's Equity Incentive Plan.

Klotho Neurosciences, Inc. CEO Joseph Sinkule received a grant of 2.5 million common shares, increasing his beneficial ownership.

Klotho Neurosciences Director Jon McGarity acquired 20,000 non-qualified stock options at an exercise price of $0.41, bringing his total direct beneficial ownership to 60,000 options.

Klotho Neurosciences, Inc. director Samuel M. Zentman acquired 20,000 non-qualified stock options at an exercise price of $0.41, bringing his total beneficial ownership to 60,000 options.

Klotho Neurosciences Director Riad El-Dada acquired 20,000 non-qualified stock options at an exercise price of $0.41, bringing his total beneficial ownership to 60,000 options.

Klotho Neurosciences CEO Joseph Sinkule acquired 400,000 shares of common stock after a portion of a non-recourse loan was canceled.

Klotho Neurosciences' Chief Financial Officer, Jeff LeBlanc, acquired 200,000 shares of common stock as part of his employment agreement.

Klotho Neurosciences Director Shalom Hirschman acquired 70,149 shares of common stock as contingent merger consideration.

Klotho Neurosciences Director Riad El-Dada acquired 10,000 non-qualified stock options at an exercise price of $0.41, increasing his total beneficial ownership of derivative securities to 40,000.

Klotho Neurosciences CEO Joseph Sinkule pledged 2 million shares as collateral for a non-recourse loan and acquired an additional 537,180 shares as merger consideration.

Klotho Neurosciences Director Jon McGarity increased his beneficial ownership through a share acquisition from merger consideration and a stock option grant.

Klotho Neurosciences Director and 10% Owner Samuel M. Zentman increased his beneficial ownership of common stock and acquired additional non-qualified stock options.

Klotho Neurosciences' Chief Financial Officer, Jeff LeBlanc, acquired 156,199 shares of common stock as contingent merger consideration.

Chardan Capital Markets LLC, along with related individuals, sold a significant number of ANEW Medical, Inc. shares over several transactions, reducing their beneficial ownership.

Redwoods Acquisition Corp. filed ANEW Medical's re-audited financial statements for 2022 and audited statements for 2023, along with unaudited financials for Q1 2024, as part of their business combination agreement.

Redwoods Acquisition Corp. files an amendment to its previous 8-K report, clarifying the redemption price per share and announcing a forward purchase agreement with Meteora Capital Partners.

Redwoods Acquisition Corp. (RWOD) has entered into a forward purchase agreement with Meteora Capital Partners to support its merger with ANEW Medical, involving the potential purchase of up to 1,000,000 shares.

Redwoods Acquisition Corp. (RWOD) has entered into a non-redemption agreement with certain investors to rescind previous redemption requests, supporting the proposed business combination with ANEW Medical, Inc.

Redwoods Acquisition Corp. stockholders voted to approve the business combination with ANEW MEDICAL, INC. at a special meeting held on April 12, 2024.

Redwoods Acquisition Corp. announces the adjournment and reconvening of its special meeting of stockholders to April 12, 2024, to vote on a proposed business combination.

Redwoods Acquisition Corp. adjourned its special meeting of stockholders on April 1, 2024, and has rescheduled it for April 8, 2024, to continue soliciting proxies for the proposed business combination.

Redwoods Acquisition Corp. has adjourned its special meeting of stockholders to April 1, 2024, and is allowing stockholders to reverse redemption requests.

Redwoods Acquisition Corp. has adjourned its special meeting of stockholders, originally scheduled for March 8, 2024, to March 22, 2024, to allow for continued proxy solicitation regarding the proposed business combination with ANEW Medical.